Jonathan Pachter
Pachter comes to the biopharmaceutical company – who focuses on drug discovery and development for oncology – from his position as head of cancer biology at OSI Pharmaceuticals; acquired by Astella.
Robert Weinberg, Verastem co-founder and co-chair of the Scientific Advisory Board, said: “Jon has been instrumental in progressing the science of EMT and cancer stem cells into the clinic.
“His ability to drive research will help Verastem deliver on the promise of new treatments for patients with incurable cancer.”